Improved oral dosing formulations of dideoxy purine nucleosides

Details Improved oral dosing formulations of dideoxy purine nucleosides Improved oral dosing formulations of dideoxy purine nucleosides

A - Human Necessities

61

K

A61K 31/70 (2006.01) A61K 9/00 (2006.01) A61K 33/08 (2006.01) A61K 33/10 (2006.01) A61K 33/12 (2006.01) A61K 33/42 (2006.01)

Patent

CA 2074215

Improved oral dosage formulations for acid-labile dideoxy purine nucleoside derivatives such as ddA, ddI, and ddG, have been developed by incorporating selected water-insoluble buffering systems in the formulation. These novel formulations provide reduced mass dosage units in the form of convenient, palatable chewable/ dispersible tablets or a dry powder sachet. The reduced mass requirement, necessary to allow tablets of reasonable size, was achieved in part by an unexpected 20 to 25% increase in drug bioavailability resulting from use of the selected buffering systems comprised of an insoluble magnesium antacid agent and either dihydroxyaluminum sodium carbonate or calcium carbonate.

Affiliated with

Also associated with

Rating

Improved oral dosing formulations of dideoxy purine nucleosides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Improved oral dosing formulations of dideoxy purine nucleosides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Improved oral dosing formulations of dideoxy purine nucleosides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1882690